RESEARCH TRIANGLE PARK, N.C. – Michael J. Leahy, MBA, a health economics and outcomes researcher and strategist with more than 20 years of experience, has joined RTI Health Solutions (RTI-HS) as Director of Health Outcomes Strategy.
“Leahy is an important hire for RTI-HS, as we expect him to add great value to our Health Outcomes Strategy (HOS) group,” said Allen Mangel, Vice President RTI-HS. “The breadth and depth of his international pharmaceutical and managed care experience will greatly supplement the existing expertise in this group.”
Comprised of a complementary team of health outcomes scientists, health economists, pricing and reimbursement experts, psychometricians, and medical writers, the HOS team synthesizes health economic and patient outcomes data to produce market access strategies, health outcomes research plans, product value assessments and dossiers, burden of illness reviews, and communication plans. “Our methods are evidence-based and help pharmaceutical clients differentiate their products by capturing the full clinical, economic and humanistic value of their drugs,” said Lori McLeod, PhD, Head of Health Outcomes Strategy.
McLeod continued, “We are very pleased Mike has joined our team. He has a valuable combination of industry experience and solid research skills and we know that he will be another key player in helping our clients accurately demonstrate the value of their products.”
Prior to joining RTI-HS, Leahy was a six-year veteran of Aventis Pharmaceutical and later Sanofi-Aventis. In his role as Senior Manager of Health Economics and Outcomes Research, Leahy was responsible for developing and implementing health economics and outcomes research strategies, studies and tactics for respiratory and oncology products. Leahy also has extensive experience in patient quality of life (QoL) research. In 2005, he led a QoL study strategy that ultimately contributed to the approval of a promotional quality of life claim for Allegra. Leahy is also credited with developing the first Academy of Managed Care Pharmacy (AMCP) Formulary Dossiers and Budget Impact Models for Allegra and Anzemet.
Prior to joining Aventis, Mike was a Principle Partner and Co-Founder of health economics and outcomes research consulting firm, PharmEcon International, where he worked with pharmaceutical companies designing and implementing cost burden of disease, medication compliance, and QoL studies. Earlier in his career, Leahy worked for managed care organizations, CIGNA and Empire Blue Cross Blue Shield where he analyzed medical claims data; studied incidence, prevalence, and cost of disease; and designed and implemented managed care information products and analytic services.
Leahy earned his BSBA and MBA from Bryant University in Rhode Island and completed post-MBA graduate coursework in health economics from the University of Connecticut. In addition to his business experience, Leahy has also held posts in academia as an Assistant Professor at Central Connecticut State University and an Adjunct Instructor at Columbia University while a full-time Research Associate in the School of Public Health. Leahy maintains active memberships in Drug Information Association (DIA), International Society of Pharmacoeconomics and Outcomes Research (ISPOR), International Society of Quality of Life (ISOQOL) and Oncology Nursing Society (ONS). As an expert researcher, Leahy has experience in many therapeutic areas including cancer, cardiovascular, ulcerative colitis, irritable bowel syndrome, allergic rhinitis, asthma and transplantation.
“I am very excited to join RTI-HS,” Leahy said. “The caliber of the staff and research produced at RTI-HS are second to none. RTI-HS is well-positioned in the health economics and outcomes research space, and I look forward to contributing to the success of the company and the satisfaction of our clients.”